No Data
No Data
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $70
Express News | Aligos Therapeutics Inc Files for Offering of up to 6.2 Mln Common Shares by the Selling Securityholders - SEC Filing
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Cuts Target Price to $70
Aligos Therapeutics Is Maintained at Buy by HC Wainwright & Co.